1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6D32F28A469FEC30985257585006C7C9D
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/building-effective-fda-relationships-and-working-with-regulators?opendocument
18
19opendocument
2018.206.194.83
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Quality, Compliance and Regulatory Regulatory Affairs

Building Effective FDA Relationships and Working with Regulators

ID: 5028


Features:

4 Info Graphics

7 Data Graphics

65 Metrics


Pages/Slides: 25


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Building Effective FDA Relationships and Working with Regulators"

STUDY OVERVIEW

New Drug Applications produce new products - the lifeblood of the pharmaceutical industry. In addition to strong science, NDAs need effective Regulatory Affairs groups to help them navigate the regulatory labyrinth that is the U.S. Food and Drug Administration. To ensure successful interactions with the FDA, officials in Regulatory Affairs groups need to establish and cultivate both formal and informal relationships with agency officials.
This study examines what communication approaches foster effective relationships between Regulatory Affairs groups and the FDA and the importance of maximizing agency interactions. Additionally, this research explores valuable tactics for working with the FDA and the importance of understanding the Washington, D.C. ecosystem.
Regulatory leaders can use the insights from this research to inform their communication approaches with regulatory officials and to compare their group’s tactics for working with the agency on filings.

KEY TOPICS

  • Executive Summary
  • Formal Relationships
  • Informal Relationships
  • Email vs. Phone Calls
  • Attending Conferences
  • Working on Relationships
  • The Role of Reputation
  • The Washington Ecosystem

KEY METRICS

  • Top Methods for Working with the FDA
  • Effectiveness of Engagement Strategies for FDA Staff
  • Ranking of FDA Organizational Levels Most Effective to Deal With
  • Rating of Informal Approaches for Building Relationships
  • Ranking of Informal Approaches for Building Relationships
  • Reputational Ranking of Top 5 Pharma Companies
  • Reputational Ranking of Top 5 Biotech Companies

SAMPLE KEY FINDINGS

  • Develop customized relationship strategies that reflect the different needs and styles of each director and FDA office. Different offices have strikingly different styles and requirements.
  • Take note of personnel and divisional idiosyncrasies within the FDA: positive and negative interactions in one place can have ripple effects for your NDA in other parts of the agency.

METHODOLOGY

The research employed a data gathering approach that gleaned quantitative data from 15 biopharma companies and one medical device company through a detailed survey. In addition, 13 Regulatory leaders participated in in-depth interviews.


Industries Profiled:
Medical Device; Biotech; Chemical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Health Care


Companies Profiled:
Medtronic; Genentech; Roche; United Therapeutics; AstraZeneca; Alcon; Bayer; Novartis; Bristol-Myers Squibb; Boehringer Ingelheim; Lilly; Amgen; Valeant; Solvay Pharmaceuticals; Merck

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.